Psilocybin Glutamate Release: The Mechanism Explained

Psilocybin Non-Serotonin Mechanisms

7T MRI

scanner used to directly measure glutamate levels in the human prefrontal cortex and hippocampus during psilocybin, providing the first direct human evidence that psilocybin alters glutamate, not just serotonin, with opposite regional effects predicting the quality of ego dissolution.

Mason et al., Neuropsychopharmacology, 2020

2 regions, 2 directions

frontal cortex glutamate rises while hippocampal glutamate falls under psilocybin, and the two directions predict opposite subjective experiences

5-HT2A → Gq → GLU

the molecular shorthand: serotonin 2A receptor activation sets off a G-protein cascade that ends with pyramidal cells releasing glutamate

mGluR2 restored

psilocybin reversed alcohol-induced depletion of the glutamate autoreceptor mGluR2 in rat prefrontal cortex, reducing craving-associated behavior

Mason et al., Neuropsychopharmacology, 2020

View as image ↗

The standard account of psilocybin begins and ends with serotonin. Psilocybin converts to psilocin, psilocin binds serotonin 2A receptors, those receptors produce the psychedelic experience. That account is correct as far as it goes. But it stops too early.

The moment psilocin activates serotonin 2A receptors in the cortex, those receptors are on a specific cell type: large pyramidal neurons that communicate using a completely different neurotransmitter, glutamate. When psilocin excites these cells through their serotonin receptors, the cells do what excited pyramidal cells do. They release glutamate. That glutamate then spreads through the frontal cortex and hippocampus, activating downstream circuits in ways that operate independently of the original serotonin signal.

This glutamate release is not a footnote to the mechanism. It has been directly measured in human brains using an ultra-high-field MRI scanner. The regional glutamate changes correlated directly with the character of the ego dissolution experience, with different brain regions showing opposite effects. And psilocybin also engages glutamate receptors (mGluR2) at the synaptic level through a mechanism that appears independent of serotonin.

This article covers the cascade from serotonin activation to glutamate release, the human evidence, and what the glutamate mechanism means for psilocybin's therapeutic effects. For the broader context on how this fits the full neuroscience picture, psilocybin and the default mode network: how it quiets the ego covers the overview. For the companion article on psilocybin's non-serotonin neurotransmitter effects more broadly, psilocybin and glutamate: beyond the serotonin story covers the wider picture.

Why Psilocybin Is Not Just a Serotonin Drug

Psilocybin's primary mechanism runs through the serotonin 2A receptor. That part of the story is well documented. What is less often explained is what happens next.

Cortical pyramidal cells are the principal excitatory neurons of the cerebral cortex. The name comes from their triangular cell body shape. They account for roughly 70-80% of all cortical neurons and release glutamate as their primary neurotransmitter, the same chemical that activates virtually all downstream excitatory circuits in the brain. When pyramidal cells fire, they do so with glutamate.

Serotonin 2A receptors are concentrated on these same pyramidal cells, particularly in layers 2 and 5 of the prefrontal and sensory cortices. When psilocin binds those receptors, it excites the pyramidal cells. The excitation is mediated by a G-protein signaling cascade that eventually depolarizes the cell. Once a pyramidal cell depolarizes past its firing threshold, it releases glutamate.

This coupling is not coincidental or indirect. The serotonin receptor and the glutamate-releasing neuron are the same cell. Every 5-HT2A activation event by psilocin is, through the pyramidal cell, a potential glutamate release event. The two neurotransmitter systems are joined at the source.

This is why understanding psilocybin's mechanism requires going beyond the receptor pharmacology. The receptor activation is step one. Glutamate release is step two. And step two unfolds in circuits and regions that are shaped by glutamate's own receptors, dynamics, and feedback systems, none of which are serotonergic.

For the serotonin receptor side of this story, how 5-HT2A agonism creates the psychedelic experience covers what happens at the 5-HT2A receptor itself. This article picks up from there.

The Molecular Cascade: How One Receptor Activation Becomes a Glutamate Surge

The pathway from psilocin binding to glutamate release has been characterized in cell preparations and rodent models. Kwan and colleagues summarized the signaling cascade in a 2022 landmark review in Nature Neuroscience.^[6]

The five steps from receptor to glutamate:

1. Psilocin binds and activates the 5-HT2A receptor on the outer surface of a cortical pyramidal cell. The receptor is a G protein-coupled receptor, meaning it is physically linked to a molecular switch (a G protein) on the inner face of the cell membrane.

2. The activated receptor switches on a Gq protein. The Gq protein is a specific type of G protein that triggers a chain of reactions inside the cell.

3. Activated Gq releases calcium stored inside the cell. Through an intermediate step involving an enzyme called phospholipase C, the activated Gq protein causes calcium ions to flood from the cell's internal stores into the cytoplasm. Calcium entering the cytoplasm is a powerful cellular activation signal.

4. Calcium and related signaling molecules push the pyramidal cell toward its firing threshold. The cell's membrane voltage becomes less negative, approaching the point where it will fire an action potential, the electrical pulse that triggers neurotransmitter release.

5. The pyramidal cell fires and releases glutamate. Glutamate enters the synaptic cleft and activates receptors on downstream neurons, propagating the signal outward through the local circuit and beyond.

This cascade does not require glutamate receptors. The trigger is serotonin 2A. The output is glutamate. The glutamate then encounters its own receptor landscape, including AMPA receptors, NMDA receptors, and metabotropic glutamate receptors, producing effects that run on glutamate's own logic, independent of the serotonin signal that started them.

What the Glutamate Surge Does: GABA, Network Effects, and the Excitation Paradox

Glutamate is excitatory. When pyramidal cells release it, neighboring neurons activate. But the cortical circuit is not a simple chain of excitation. Some of the neurons most responsive to pyramidal cell glutamate are GABAergic interneurons, inhibitory cells that suppress surrounding pyramidal cell activity when activated.

This creates a counterintuitive feedback loop. Psilocybin excites pyramidal cells through their serotonin receptors. Those cells release glutamate. The glutamate activates GABAergic interneurons. The GABAergic interneurons inhibit nearby pyramidal cells. What begins as excitation ends, partly, as inhibition.

A 2024 systematic review by Szpregiel and colleagues specifically identified this excitatory-then-inhibitory cascade as a key contributor to psilocybin's antidepressant mechanism.^[1] The glutamate-driven activation of inhibitory interneurons produces downstream neuroplasticity effects (changes in how neural circuits reorganize) that operate independently of any direct serotonin action.

The result in the prefrontal cortex is not simple over-excitation. It is a pattern of excitatory bursts interleaved with inhibitory correction, producing the unusual oscillatory dynamics associated with the psychedelic state. Smausz and colleagues argued in a 2022 review that understanding this interplay requires direct in vivo electrophysiology, meaning recording from neurons in living, behaving animals, because the dynamics are too fast and too circuit-specific to resolve with brain imaging alone.^[4] This research is ongoing and most of the glutamate-GABA dynamics discussed here are from preclinical models.

Inside the 7T MRI Scanner: The Human Proof That Psilocybin Changes Glutamate

All of the above is well-supported in preclinical work. The Mason 2020 study moved it into humans.^[2]

The technique is called magnetic resonance spectroscopy (MRS), a variant of standard MRI. While conventional MRI detects which brain regions are active, MRS measures the chemical composition of a specified patch of tissue, including the concentration of neurotransmitters and other metabolites. At 7 Tesla (7T, roughly twice the field strength of advanced hospital scanners), MRS can detect neurotransmitter concentrations that would be invisible at lower field strengths. The researchers positioned the measurement region over the medial prefrontal cortex and hippocampus separately and measured glutamate before and during a psilocybin session.

The findings were specific. Medial prefrontal cortex glutamate increased after psilocybin. The larger the glutamate increase, the more difficult the ego dissolution experience felt: more anxiety, less sense of control, more disorientation. Hippocampal glutamate decreased. The larger the decrease, the more positive the ego dissolution experience was: more feelings of unity, oceanic expansiveness, and peace.

The same drug. Two brain regions. Opposite glutamate changes. Opposite experiential correlates.

This regional specificity matters. It shows that psilocybin does not simply flood the brain with glutamate. It produces structured, region-specific glutamate changes that correspond to the geography of the subjective experience. The frontal cortex, the seat of self-monitoring, planning, and critical evaluation, becomes more glutamate-active, which appears to correlate with the more challenging aspects of the ego dissolution. The hippocampus, involved in contextualizing experience and integrating memory with emotion, becomes less glutamate-active, which appears to correlate with the more transcendent aspects.

This is not purely a serotonin story. The regional glutamate changes are the serotonin effect's downstream signature.

mGluR2: The Glutamate Brake That Psilocybin Can Restore

Metabotropic glutamate receptor 2 (mGluR2) is a receptor that responds to glutamate, but through a modulatory rather than fast-excitatory mechanism. It sits on the presynaptic side of synapses, the output end of the sending neuron, where it acts as an autoreceptor. When glutamate accumulates in the synaptic cleft, mGluR2 detects it and sends a signal back to the presynaptic neuron to reduce further glutamate release. It is a feedback brake on excessive glutamate.

In chronic alcohol use, mGluR2 expression in the prefrontal cortex drops. The glutamate brake weakens. Glutamate stays elevated, contributing to the cognitive dysregulation and persistent craving that characterize alcohol use disorder.

Meinhardt and colleagues found that a single dose of psilocybin reversed this mGluR2 downregulation in the prefrontal cortex of alcohol-exposed rats, restoring normal glutamate receptor density and reducing craving-associated behavior.^[3] The mechanism identified: psilocybin restored mGluR2 levels, which reinstated the synaptic glutamate feedback system.

This is significant for two reasons. First, it is the most direct evidence that psilocybin engages the glutamate receptor system as an independent therapeutic mechanism, not just as a downstream consequence of serotonin activation. The mGluR2 restoration occurs at a glutamate receptor, and it produces functional consequences, including reduced craving, that are specifically glutamatergic. Second, it explains why psilocybin's glutamate effects are not like excitotoxicity (the harmful glutamate excess seen in stroke or seizure). Psilocybin appears to restore glutamate regulation, not overwhelm it.

The limitation: this is an alcohol model in rats. Whether the same mGluR2 restoration occurs in humans, in non-alcohol-exposed people, or in people with depression rather than addiction is not yet established.

How Glutamate-Driven Plasticity May Explain Psilocybin's Antidepressant Speed

Conventional antidepressants primarily target serotonin or norepinephrine reuptake. They take two to four weeks to produce therapeutic effects, because their mechanism depends on slow adaptations in receptor sensitivity and gene expression over that timeline.

Psilocybin's antidepressant effects, by contrast, can appear within days of a single session and persist for months. The serotonin receptor story alone does not fully account for this timescale difference.

The glutamate cascade provides part of the explanation. When pyramidal cells release glutamate following 5-HT2A activation, that glutamate activates downstream signaling pathways in postsynaptic neurons, including mTOR (the cell growth regulator) and BDNF signaling, which drives structural neuroplasticity. Szpregiel's 2024 review identified this glutamate-mediated plasticity as a contributor to psilocybin's antidepressant mechanism that operates independently of the serotonin receptor activation that initiated it.^[1]

This suggests a two-pathway model for psilocybin's antidepressant effects. The serotonin path: 5-HT2A activation produces the acute altered state, and the psychological processing that happens during that state may produce lasting cognitive changes. The glutamate path: 5-HT2A activation produces glutamate release, which triggers plasticity signaling, which produces structural brain changes that outlast both the drug and the acute experience.

The two paths begin at the same receptor. They diverge in their mechanisms, timescales, and functional consequences. Doss and colleagues' 2022 review of circuit-level models reinforced that psilocybin's effects cannot be explained by any single mechanism: the CSTC model, the REBUS model, and the CCC model each capture different aspects of what is clearly a multi-system phenomenon.^[5]

For how the claustrum connects to these same glutamate dynamics, the claustrum and psilocybin: a new theory of consciousness covers that circuit. For how the thalamic gating mechanism relates, thalamic gating and psilocybin: how it floods the brain with input goes deeper there.

The Evidence Limits: What We Can and Cannot Conclude

Most of the molecular cascade evidence is preclinical. The five-step pathway from 5-HT2A binding to glutamate release is characterized in isolated cell preparations and rodent models; it has not been traced at each step in the intact human brain.

The Mason 2020 MRS data is the primary human evidence, and it is genuinely strong: direct chemical measurement in human brain tissue during psilocybin, with dose-matched correlations to subjective experience. But it involved a specific dose (0.17 mg/kg), a specific patient population, and a specific subjective state (ego dissolution). MRS also measures total glutamate concentration in a voxel of tissue, which includes glutamate in synapses, in cells, in astrocytes, and in metabolic pools; it cannot isolate synaptic glutamate release specifically.

Smausz and colleagues made this limitation explicit in their 2022 review.^[4] They argued that in vivo electrophysiology, meaning recording from neurons in living animals, is the necessary next step to understand how the cascade unfolds in intact circuits. The glutamate-GABA dynamics, the oscillatory changes, and the interaction with thalamic gating all require recording methods that brain imaging cannot provide.

The mGluR2 finding from Meinhardt 2021 is from an alcohol-exposed rodent model, which is not directly translatable to human depression or to non-addicted brains. Whether psilocybin modulates mGluR2 in human prefrontal cortex under standard conditions is an open question.

What the data establishes: psilocybin triggers glutamate changes in the human brain, those changes are region-specific and experientially meaningful, and psilocybin engages glutamate receptors through mechanisms that operate independently of serotonin. How that all plays out in the full complexity of the living human brain is an active area of research.

For the broader context on psilocybin's other non-serotonin receptor interactions, including its relationship to receptors beyond serotonin 2A, beyond 5-HT2A: other serotonin receptors psilocybin activates covers that territory.

The Bottom Line

Psilocybin's serotonin 2A receptor activation triggers a molecular cascade that ends with glutamate release from cortical pyramidal cells, producing region-specific changes in the frontal cortex and hippocampus that have been directly measured in humans using 7T MRI. The 2020 Mason study showed that prefrontal glutamate increase correlates with negatively-experienced ego dissolution while hippocampal glutamate decrease correlates with positive ego dissolution. A 2021 study found psilocybin also directly engages mGluR2 glutamate receptors in the prefrontal cortex, restoring glutamate homeostasis in an addiction model. The glutamate-driven plasticity cascade is a candidate mechanism for psilocybin's antidepressant effects that operates alongside, and independently from, the serotonin mechanism.

Frequently Asked Questions

How does psilocybin cause glutamate release?

Psilocybin causes glutamate release through a five-step molecular cascade. Psilocin binds the 5-HT2A receptor on cortical pyramidal cells; the receptor activates a Gq signaling protein inside the cell; the Gq protein triggers calcium release from internal stores; calcium floods the cytoplasm and pushes the cell toward firing; the cell fires and releases glutamate into the synapse. This cascade was characterized by Kwan et al. (Nature Neuroscience, 2022) and confirmed as functionally significant in frontal cortex and hippocampus by Szpregiel et al. (Pharmacological Reports, 2024).

What is the mechanism of psilocybin beyond serotonin?

Psilocybin's primary receptor is serotonin 2A, but several mechanisms operate beyond that initial binding. The most direct is the glutamate cascade: 5-HT2A activation on pyramidal cells triggers glutamate release, which activates GABA interneurons and drives downstream plasticity signaling (mTOR, BDNF) independently of any further serotonin receptor activity. Kwan et al. (Nature Neuroscience, 2022) characterized psychedelics as multi-system brain modifiers that activate G-protein cascades, alter thalamocortical connectivity, and produce lasting structural plasticity through pathways that diverge from the original serotonin activation. Psilocybin also directly modulates mGluR2 glutamate receptors in prefrontal cortex, as shown in the Meinhardt 2021 addiction model.

Does psilocybin increase glutamate in the brain?

Yes, but the answer depends on which brain region. A 2020 human MRI spectroscopy study (Mason et al., Neuropsychopharmacology) found that psilocybin increased glutamate in the medial prefrontal cortex while simultaneously decreasing it in the hippocampus. The prefrontal increase correlated with difficult aspects of ego dissolution; the hippocampal decrease correlated with positive aspects. Psilocybin does not uniformly increase glutamate across the whole brain. It produces region-specific changes, and those differences correspond to distinct subjective effects.

What is mGluR2 and how does psilocybin affect it?

mGluR2 (metabotropic glutamate receptor 2) is a presynaptic glutamate autoreceptor that acts as a feedback brake on glutamate release: when glutamate builds up in a synapse, mGluR2 detects it and signals the presynaptic neuron to release less. In alcohol use disorder, chronic alcohol exposure reduces mGluR2 expression in the prefrontal cortex, weakening this brake and contributing to glutamate dysregulation and craving. Meinhardt et al. (Science Advances, 2021) found that psilocybin reversed this mGluR2 downregulation in alcohol-exposed rat prefrontal cortex, restoring glutamate homeostasis and reducing craving behavior. This is the most direct evidence that psilocybin modulates glutamate receptors directly, not just as a downstream serotonin effect.

Why is glutamate important for the antidepressant effects of psilocybin?

Glutamate matters for psilocybin's antidepressant effects because the glutamate cascade activates plasticity-promoting pathways (mTOR, BDNF signaling) that can change brain structure independently of the serotonin receptor activation that triggered the glutamate release. This creates a second antidepressant pathway: while the serotonin path produces the acute altered state, the glutamate path drives structural neuroplasticity that may outlast both the drug session and the subjective experience. Szpregiel et al. (Pharmacological Reports, 2024) identified glutamate-mediated neuroplasticity as a key contributor to psilocybin's antidepressant mechanism independent of direct serotonin effects. The glutamate pathway may also explain why ketamine (which works primarily through glutamate NMDA receptors) and psilocybin produce rapid antidepressant effects on similar timescales despite targeting different primary receptors.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6. Source details for this reference are not yet available.